000			03087cam a2200349 a 4500
003			EG-GiCUC
005			20250223032234.0
008			190401s2018 ua f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.19.05.M.Sc.2018.Da.O
100	0		_aDalia Magdy Abdelmasseih
245	1	4	_aThe outcome of relapsed wilms{u2019} tumor cases at National cancer institute, Cairo university, Egypt / _cDalia Magdy Abdelmasseih ; Supervised Lobna Shalaby , Wael Zekri Khaled , Asmaa Ibrahim
246	1	5	_aنتائج حالات ورم ويلمز المرتد فى المعهد القومى للأورام مصر
260			_aCairo : _bDalia Magdy Abdelmasseih , _c2018
300			_a149 P. ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aBackground: Although the overall relapse rate for children with WT has decreased to less than 15%, the overall long-term survival for patients with recurrent disease remains at approximately 50%. A combination of chemotherapy and molecularly targeted therapies will likely be necessary to push the post-relapse survival rate beyond 90%. Methods: There were 130 pediatric cases diagnosed with Wilms{u2019} tumor between the years 2008 and 2015 at the National cancer institute, Cairo university, Egypt. From these cases, 30 had relapsed. We were concerned with collecting information at initial disease phase and at relapse phase. Certain factors were analysed in relevance to survival: these were age, gender, initial tumor stage, initial histology, time to relapse from nephrectomy and from diagnosis, site of relapse and radiotherapy received at relapse. Most studied patients were treated according to the modified COG protocol. Objectives: Our study aimed at estimating the overall survival (OS) and event free survival (EFS) for the relapsed cases and to correlate the survival rates with the different risk factors. Results: The median follow up period was 22.3 months (ranged from 3.6 to 140.7 months). The OS was 30.9% while the EFS was 29.8% at a 5-year follow up period. The median age at diagnosis in our study was 4 years (48 months) with a mean of 4.4 years (52.8 months). Median time from diagnosis to relapse in our study was 14.4 months. A second complete remission was attained in 18/30 patients (60%). The final outcome of the 30 patients; 10 are alive and 19 had died. One patient has travelled to Sudan while in CR. Two factors in our univariate analysis were prognostically significant for survival after relapse
530			_aIssued also as CD
653		4	_aNational Cancer Institute
653		4	_aThe outcome of relapsed wilms{u2019} tumor cases
653		4	_aWilms{u2019} tumor
700	0		_aAsmaa Ibrahim , _eSupervisor
700	0		_aLobna Shalaby , _eSupervisor
700	0		_aWael Zekri Khaled , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c71127 _d71127